Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to buy the biotech. And there's another $512.5 million on the table should Pfizer exercise its option, with the deal hinging on the biotech's successful completion of a Phase II study of a new treatment for acute kidney injury (AKI) related to sepsis.
Rare disease biotech Alexion is blueprinting a major expansion in Ireland, planning to spend €450 million ($500 million) and hire 200 workers over four years as it forecasts a bright future for its business model.
A struggling GlaxoSmithKline has set up an economy-sized research spinout with the University of North Carolina at Chapel Hill that's short on cash and long--very, very long--on its promise to hunt for a cure for HIV.
Actavis is rolling toward a Phase III trial with an eye treatment licensed from Switzerland's Molecular Partners, following through on a promise made in the lead-up to its $66 billion acquisition of Allergan.
Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.
IBM has continued its push into healthcare and research by striking deals with electronic health record software provider Epic, Mayo Clinic and 14 cancer institutes.
Canada's Concordia Healthcare is initiating a Phase II study to expand the use of its Photofrin combination therapy to include adults with high-grade gliomas, a class of brain and spinal cord tumors, as it continues to aggressively expand the indication of the product to include more forms of cancer.
Apple has designs on the DNA sequencing sector. The tech giant is reportedly working with researchers to make 23andMe-style DNA sequencing spit kits part of ResearchKit, the platform that turned every iPhone user into a potential study participant.
Surface Oncology, an immunotherapy-focused startup from Atlas Venture, has poached AstraZeneca's former chief cancer strategist to serve as its CEO, beating a path toward clinical development.
After the first closing of a Series B round Wednesday, Themis Bioscience will have an infusion of €7 million ($7.9 million) to work with as it ushers its Chikungunya fever vaccine into Phase II and welcomes a new chairman and two new board members.